Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143840
Corporate User License Price USD 6000
Corporate User License Price INR 431520
Site License Price USD 4000
Site License Price INR 287680
Request a Quote

Report Title

Epstein-Barr Viral Infections-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Epstein-Barr Viral Infections-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Epstein-Barr Viral Infections-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Epstein-Barr Viral Infections-Pipeline Review, H2 2016



Executive Summary

Epstein-Barr Viral Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Epstein-Barr Viral Infections-Pipeline Review, H2 2016', provides an overview of the Epstein-Barr Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections

The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects

The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Epstein-Barr Viral Infections Overview 9

Therapeutics Development 10

Pipeline Products for Epstein-Barr Viral Infections-Overview 10

Pipeline Products for Epstein-Barr Viral Infections-Comparative Analysis 11

Epstein-Barr Viral Infections-Therapeutics under Development by Companies 12

Epstein-Barr Viral Infections-Therapeutics under Investigation by Universities/Institutes 13

Epstein-Barr Viral Infections-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Epstein-Barr Viral Infections-Products under Development by Companies 17

Epstein-Barr Viral Infections-Products under Investigation by Universities/Institutes 18

Epstein-Barr Viral Infections-Companies Involved in Therapeutics Development 19

Arno Therapeutics, Inc. 19

Cell Medica Limited 20

Epiphany Biosciences, Inc. 21

Genocea Biosciences, Inc. 22

Humabs BioMed SA 23

Molplex Ltd. 24

Omeros Corporation 25

Savoy Pharmaceuticals, Inc. 26

Theravectys SA 27

Vironika, LLC 28

ViroStatics srl 29

Epstein-Barr Viral Infections-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

AR-12-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Cellular Immunotherapy for EBV Associated PTLD-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Cellular Immunotherapy for Infectious Disease-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Cellular Immunotherapy for Infectious Diseases-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Cellular Immunotherapy for Viral Infections-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Cellular Immunotherapy for Viral Infections Post-HSCT-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CMD-003-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Epstein-Barr virus (virus like particle) vaccine-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Epstein-Barr virus vaccine-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Monoclonal Antibody for Epstein-Barr Viral Infection-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

MVA vaccine-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecule for Infectious Mononucleosis-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Vaccine for Epstein-Barr Virus and Oncology-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

valomaciclovir stearate-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Viroprev-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Epstein-Barr Viral Infections-Dormant Projects 68

Epstein-Barr Viral Infections-Product Development Milestones 69

Featured News & Press Releases 69

Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Epstein-Barr Viral Infections, H2 2016 10

Number of Products under Development for Epstein-Barr Viral Infections-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Epstein-Barr Viral Infections-Pipeline by Arno Therapeutics, Inc., H2 2016 19

Epstein-Barr Viral Infections-Pipeline by Cell Medica Limited, H2 2016 20

Epstein-Barr Viral Infections-Pipeline by Epiphany Biosciences, Inc., H2 2016 21

Epstein-Barr Viral Infections-Pipeline by Genocea Biosciences, Inc., H2 2016 22

Epstein-Barr Viral Infections-Pipeline by Humabs BioMed SA, H2 2016 23

Epstein-Barr Viral Infections-Pipeline by Molplex Ltd., H2 2016 24

Epstein-Barr Viral Infections-Pipeline by Omeros Corporation, H2 2016 25

Epstein-Barr Viral Infections-Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 26

Epstein-Barr Viral Infections-Pipeline by Theravectys SA, H2 2016 27

Epstein-Barr Viral Infections-Pipeline by Vironika, LLC, H2 2016 28

Epstein-Barr Viral Infections-Pipeline by ViroStatics srl, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 34

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Epstein-Barr Viral Infections-Dormant Projects, H2 2016 68

List of Figures

Number of Products under Development for Epstein-Barr Viral Infections, H2 2016 10

Number of Products under Development for Epstein-Barr Viral Infections-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 31

Number of Products by Stage and Top 10 Targets, H2 2016 31

Number of Products by Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Types, H2 2016 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Arno Therapeutics, Inc.

Cell Medica Limited

Epiphany Biosciences, Inc.

Genocea Biosciences, Inc.

Humabs BioMed SA

Molplex Ltd.

Omeros Corporation

Savoy Pharmaceuticals, Inc.

Theravectys SA

Vironika, LLC

ViroStatics srl

Epstein-Barr Viral Infections Therapeutic Products under Development, Key Players in Epstein-Barr Viral Infections Therapeutics, Epstein-Barr Viral Infections Pipeline Overview, Epstein-Barr Viral Infections Pipeline, Epstein-Barr Viral Infections Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand